Apply to trial NCT05183984

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening